CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Income Statement [Abstract]
Net revenues	$ 115,925	$ 86,713	$ 217,753	$ 160,022	$ 351,318
Cost of revenues	25,474	21,106	49,970	40,920	88,606
Gross profit	90,451	65,607	167,783	119,102	262,712
Operating costs and expenses:
Research, development and clinical trials	29,918	19,454	55,190	36,496	79,003
Sales and marketing	28,461	23,708	57,294	46,041	96,675
General and administrative	25,404	21,249	52,012	41,487	87,948
Total operating costs and expenses	83,783	64,411	164,496	124,024	263,626
Operating income (loss)	6,668	1,196	3,287	(4,922)	(914)
Financial expenses (income), net	2,617	1,239	5,049	3,610	7,910
Income (loss) before income tax	4,051	(43)	(1,762)	(8,532)	(8,824)
Income tax	2,396	1,227	(7,369)	4,888	(1,594)
Net income (loss)	$ 1,655	$ (1,270)	$ 5,607	$ (13,420)	$ (7,230)
Basic net income (loss) per ordinary share (in usd per share)	$ 0.02	$ (0.01)	$ 0.06	$ (0.14)	$ (0.07)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	100,718,893	96,356,317	100,298,230	95,583,802	97,237,549
Diluted net income (loss) per ordinary share (in usd per share)	$ 0.02	$ (0.01)	$ 0.05	$ (0.14)	$ (0.07)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	107,647,802	96,356,317	107,897,907	95,583,802	97,237,549